Diamyd Medical AB (publ) (DMYD_B) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hi, and welcome to this live broadcast from BioStock Studio. In Tänselvik, Diarmuid Medical have announced a financing agreement with US specialist investors and this morning published their Q2 report. We are joined by CEO Ulf Harnedius and CFO Niklas Axelsson, who are here to tell us more. And don't forget that the live chat is open, so just send in your questions and the gentleman will answer them after a brief presentation. And with that, I hand it over to you, Ulf. Welcome, everyone, and I'll start off here by giving you a brief sort of run through the main achievements milestones during this period and also some of the upcoming milestones. And then Niklas will follow with a bit more of a deep dive into the financials. So let's start off here by Just a second here. So it's been, as always, a very intense, intense period and maybe especially intense now as we are getting close to the first interim readout in the phase three trial. So with the milestones that we have achieved, first of all, full enrollment in the phase three trial that is running in Europe and US. So we now have 321 patients enrolled and it's now fully randomized. And this, I must say, is quite a monumental achievement by the team because we have screened patients worth of actually two phase three trials here. We have screened more than 800 patients and now we have 321. the trial and again as a reminder this is the first ever precision medicine trial ever done in in type 1 diabetes meaning that we go for a specific genetic subgroup of the disease and this is also why it's especially challenging to actually recruit for these kinds of trials and again these our clinical sites have never done a a trial like this so This is truly an achievement by the team to have achieved more than 300 patients in the...